FindTrial
Sign In

A phase III study of KW-3357

A clinical study of KW-3357 in patients diagnosed as disseminated intravascular coagulation (DIC) by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221496
Enrollment
Unknown
Registered
2011-06-28
Start date
2011-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disseminated intravascular coagulation (DIC)

Interventions

investigational material(s) Generic name etc : KW-3357 INN of investigational material : Therapeutic category code : 634 Human blood preparations Dosage and Administration for Investigational materia

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Diagnosed or suspected as DIC by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare - Antithrombin activity <= 70% - Written informed consent from patient or guardian

Exclusion criteria

Exclusion criteria: - Anamnesis or complication of serious drug allergy - Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis - Pregnant, nursing, or possibly pregnant woman - Possibility for the promotion of bleeding by concomitant use of heparin

Design outcomes

Primary

MeasureTime frame
Safety DIC resolution DIC score Mortality Plasma antithrombin activity—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026